Keyphrases
Randomized Controlled Trial
100%
Bipolar Disorder
100%
Pramipexole
100%
Dopamine Agonist
28%
Neurocognitive Impairment
28%
Mean Group
28%
MATRICS Consensus Cognitive Battery
28%
Composite Score
14%
Quality of Life
14%
Clinically Significant
14%
Placebo Groups
14%
Placebo
14%
Serious Adverse Events
14%
Healthy Volunteers
14%
Neurocognitive Function
14%
Cognitive Deficits
14%
Treatment Group
14%
Personalized Approach
14%
Neurobiology
14%
Mild Cognitive Impairment
14%
Mixed Models
14%
Double-blind Placebo-controlled Trial
14%
Cognitive Enhancement
14%
Affect Responses
14%
Cognitive Subgroups
14%
Bipolar II Disorder
14%
Bipolar I Disorder
14%
Cohen's d
14%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Bipolar Disorder
100%
Pramipexole
100%
Placebo
42%
Cognitive Defect
28%
Dopamine Receptor Stimulating Agent
28%
Adverse Event
14%
Normal Human
14%
Mixed Model
14%
Bipolar II Disorder
14%
Bipolar I Disorder
14%
Neuroscience
Randomized Controlled Trial
100%
Bipolar Disorder
100%
Pramipexole
100%
Placebo
42%
Cognitive Disorders
28%
Dopamine Agonist
28%
Bipolar II Disorder
14%
Bipolar I Disorder
14%
Neurobiology
14%
Psychology
Bipolar Disorder
100%
Mood
25%
Cognitive Deficit
25%
Composite Score
12%
Quality of Life
12%
Mixed Model
12%
Neurobiology
12%
Neurocognitive Function
12%